Literature DB >> 19016531

B-cell responses to B-cell activation factor of the TNF family (BAFF) are impaired in the absence of PI3K delta.

Thomas Henley1, Dorottya Kovesdi, Martin Turner.   

Abstract

B-cell activating factor of the TNF family (BAFF) is critical for the survival and maturation of B cells. The molecular mechanisms by which BAFF regulates the survival of developing B cells are becoming better understood. Recent evidence has begun to emerge demonstrating a role for the PI3K/Akt signalling pathway in response to BAFF. However, the importance of the PI3K family for BAFF-signalling and the effects of loss of PI3K function on BAFF responses are still unknown. We therefore investigated the BAFF-mediated responses of B cells deficient for the PI3K catalytic subunit P110delta. We find that the loss of P110delta impairs the BAFF-mediated survival of cultured B cells demonstrating a direct role for this member of the PI3K family in regulating the survival of B cells in response to BAFF. P110delta was required for the growth of B cells in response to BAFF and was critical for the upregulation of the receptor for BAFF following BCR crosslinking. Our findings reveal an important role for p110delta in regulating B-cell responses to BAFF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19016531     DOI: 10.1002/eji.200838618

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  35 in total

Review 1.  BAFF and selection of autoreactive B cells.

Authors:  Zheng Liu; Anne Davidson
Journal:  Trends Immunol       Date:  2011-07-13       Impact factor: 16.687

2.  B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in lymphoma B cells.

Authors:  Frank Secreto; Michelle Manske; Tammy Price-Troska; Steven Ziesmer; Lucy S Hodge; Stephen M Ansell; James R Cerhan; Anne J Novak
Journal:  Leuk Lymphoma       Date:  2014-02-24

Review 3.  Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease.

Authors:  Robert C Rickert; Julia Jellusova; Ana V Miletic
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

Review 4.  The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia.

Authors:  Kruti Sheth Nair; Bruce Cheson
Journal:  Ther Adv Hematol       Date:  2016-02-03

Review 5.  The biology behind PI3K inhibition in chronic lymphocytic leukaemia.

Authors:  Valentín Ortiz-Maldonado; Marcial García-Morillo; Julio Delgado
Journal:  Ther Adv Hematol       Date:  2015-02

Review 6.  Metabolic Regulation of the Immune Humoral Response.

Authors:  Mark Boothby; Robert C Rickert
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

Review 7.  PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.

Authors:  Lomon So; David A Fruman
Journal:  Biochem J       Date:  2012-03-15       Impact factor: 3.857

Review 8.  BAFF inhibition in SLE-Is tolerance restored?

Authors:  Shaun W Jackson; Anne Davidson
Journal:  Immunol Rev       Date:  2019-09-28       Impact factor: 12.988

9.  The development of mature B lymphocytes requires the combined function of CD19 and the p110δ subunit of PI3K.

Authors:  Dorottya Kövesdi; Sarah E Bell; Martin Turner
Journal:  Self Nonself       Date:  2010-03-11

10.  Context-specific BAFF-R signaling by the NF-κB and PI3K pathways.

Authors:  Julia Jellusova; Ana V Miletic; Matthew H Cato; Wai-Wai Lin; Yinling Hu; Gail A Bishop; Mark J Shlomchik; Robert C Rickert
Journal:  Cell Rep       Date:  2013-11-14       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.